Ethnological aspects of COVID-19
DOI:
https://doi.org/10.1590/s2175-97902022e20975Keywords:
Coronavirus, COVID-19, Immune system, MERS, SARSAbstract
Within recent past, coronavirus has shaken the whole world. The world faced a new pandemic of novel coronavirus 2019 (SARS-CoV-2/ COVID-19).It has socioeconomically impacted world population a lot in terms of education, economy as well as physical and mental health. This novel coronavirus is notorious enough that put human health at a great risk. Currently, researchers all over the world aretrying hard to develop a new drug/vaccine for its treatment. In past decades, the world population has faced various viral infectious illness outbreaks. Influenza A, Ebola, Zika, SARS and MERS viruses had whacked public health and economy. Medical science technology achieved the landmark in developing coronavirus (SARS-CoV-2) vaccines that are approved currently for emergency use. Some of the recently approved vaccines are developed by Pfizer and Moderna, Johnson and Johnson, Gam-COVID-vac (Sputnik V), Bharat Biotech (covaxin) andOxford-AstraZeneca vaccines (covishield) (Badenet al., 2021). Here, a short review is drafted focusingon infection, immune system, pathogenesis, phylogenesis, mode of transmission and impact of coronavirus on health and economy and recent developments in treating COVID-19.
Downloads
References
Allen F, Carletti E. An overview of the crisis: Causes, consequences, and solutions. Int Rev Finance. 2010;10(1):1-26.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.
Badgujar KC, Badgujar VC, Badgujar SB. Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges. Diabetes Metab Syndr. 2020;14(5):1361-1376.
Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Eur J Clin Invest. 2020;50(3):e13209.
Boopathi S, Poma AB, Kolandaivel P. Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2021;39(9):3409-3418.
Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2-41.
Casadevall A, Pirofski LA. Microbiology: ditch the term pathogen. Nat News. 2014;516(7530):165.
Casadevall A, Pirofski LA. What is a host? Incorporating the microbiota into the damage-response framework. Infect immun. 2015;83(1):2-7.
Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.
Cooper JW, Gunn C, Carter SJ. Cooper and Gunn’s Tutorial Pharmacy. Edited by SJ Carter, Pitman Medical, London. 1972.
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al.SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567-71.
Cortez MH, Weitz JS. Distinguishing between indirect and direct modes of transmission using epidemiological time series. Am Nat. 2013,181(2):E43-E52.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157.
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-192.
Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718-725.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478.
Gaiotti E. Credit availability and investment: Lessons from the “great recession”. Eur Eco Rev. 2013;59:212-227.
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
Hoglund C. Evaluation of microbial health risks associated with the reuse of source-separated human urine (7th edn). Bioteknologi, Stockholm, Sweden. 2001. p.78.
Holmes KV, Behnke JN. Evolution of a Coronavirus during Persistent Infection inVitro. In Biochemistry and biology of coronaviruses. Springer, Boston, MA;1981. p.287-299.
<<http://www.chictr.org.cn/showprojen.aspx?proj=52227>>
» http://www.chictr.org.cn/showprojen.aspx?proj=52227
<<https://clinicaltrials.gov/ct2/show/NCT04327206>>
» https://clinicaltrials.gov/ct2/show/NCT04327206
<<https://clinicaltrials.gov/ct2/show/NCT04328441>>
» https://clinicaltrials.gov/ct2/show/NCT04328441
<<https://clinicaltrials.gov/ct2/show/NCT04341389>>
» https://clinicaltrials.gov/ct2/show/NCT04341389
<<https://clinicaltrials.gov/ct2/show/record/NCT04276896>>
» https://clinicaltrials.gov/ct2/show/record/NCT04276896
<<https://clinicaltrials.gov/ct2/show/record/NCT04313127>>
» https://clinicaltrials.gov/ct2/show/record/NCT04313127
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infectedwith 2019 novel coronavirus in Wuhan. China. Lancet . 2020;395(10223):497-506.
Jagannathan R, Kapoor M, Schaumburg E. Causes of the great recession of 2007-2009: The financial crisis was the symptom not the disease. J Financ Intermed. 2013;22(1):4-29.
Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-632.
Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.
Koenig KL. Identify-Isolate-Inform: A modified tool for initial detection and management of Middle East Respiratory Syndrome patients in the emergency department. West J Emerg Med. 2015;16(5):619.
Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):18-18.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet . 2021;397(10275):671-681.
Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. J Med Virol . 2020;92(4):401-402.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet . 2020;395(10224):565-574.
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90.
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature . 2020;586(7830):589-93.
Nidom RV, Indrasari S, Normalina I, Nidom AN, Afifah B, Dewi L, et al. An updated investigation prior to COVID-19 Vaccination Program in Indonesia: Full-length genome mutation analysis of SARS-CoV-2. bioRxiv. 2021.
Ozili PK, Arun T. Spillover of COVID-19: impact on the Global Economy. Available at SSRN 3562570. 2020.
Ozili PK. 100 Quotes from the Global Financial Crisis: Lessons for the future. Available at SSRN 3500921.2020.
Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Eng J Med. 2020;383(27):2603-2615.
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J. 2020 (in press)
Schroeder Jr HW, Cavacini L. Structure and function of immune globulins. J Allergy Clin Immunol.2020;125:41-52.
Shen M, Zhou Y, Ye J, Al-Maskri AA, Kang Y, Zeng S, et al. Recent advances and perspectives of nucleic acid detection for coronavirus. J Pharm Biomed Anal. 2020;10(2):97-101.
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.
Siordia Jr JA. Epidemiology and clinical features of COVID-19: A review of current literature. J Clin Virol. 2020;127:104357.
Smith TR, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat commun. 2020;11(1):1-3.
Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020
Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-385.
Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11(515):eaax5866
Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol . 2010;125(2 Suppl 2):S24-S32.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet . 2021;397(10269):99-111.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20.
Wang H, Yuntao Z, Baoying H, Wei D, Yaru Q, Wenling W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020c;182(3):713-721.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020a;30(3):269-271.
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol . 2020;92(4):441-447.
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020b;14(1):64-68.
Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature . 2020;581(7809):465-469.
Yadav PD, Potdar VA, Choudhary ML, Nyayanit DA, Agrawal M, Jadhav SM, et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J Med Res. 2020;151(2-3):200.
Yang W, Yan F. Patients with RT-PCR-confirmed COVID-19 and normal chest CT. Radiology. 2020;295(2):E3-E3.
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
